Prospective cohort study of neoadjuvant chemotherapy using tri-weekly carboplatin and weekly paclitaxel for patients with locally advanced cervical cancer

Prospective cohort study of neoadjuvant chemotherapy using tri-weekly carboplatin and weekly paclitaxel for patients with locally advanced cervical cancer - CC-NAC

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024136

Enrollment

100

Registered

2016-10-01

Start date

2016-09-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

Neoadjuvant chemotherapy (3 cycles of dose dense TC therapy)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Histologically proven cervical cancer. 2. FIGO stage Ib2, IIa2, IIb. 3. ECOG Performance Status: 0 to 2.

Exclusion criteria

Exclusion criteria: 1. Previous chemotherapy. 2. Concomitant malignancy. 3. Severe complication.

Design outcomes

Primary

Measure	Time frame
2 year recurrence free survival rate	—

Secondary

Measure	Time frame
Response rate, Pathological CR rate, 2 year overall survival rate, Toxicity, Site of recurrence, Completion rate of the neoadjuvant chemotherapy	—

Countries

Japan

Contacts

Public ContactShoji Nagao

Hyogo Cancer Center Gynecologic Oncology

nagao@hp.pref.hyogo.jp078-929-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026